AI Article Synopsis
- The obesity epidemic is driven by the easy access to calorie-rich foods and low physical activity levels, leading to an energy imbalance where excess calories convert to body fat.
- Current body mechanisms primarily protect against starvation rather than prevent obesity, highlighting a gap in weight regulation.
- Recent research has focused on gastrointestinal hormones as potential treatments for obesity, specifically targeting hormones like oxyntomodulin, peptide YY, GLP-1, pancreatic polypeptide, and ghrelin.
Article Abstract
The current obesity epidemic is fuelled by the availability of highly palatable, calorie-dense food, and the low requirement for physical activity in our modern environment. If energy intake exceeds energy use, the excess calories are stored as body fat. Although the body has mechanisms that act to maintain body weight over time, they primarily defend against starvation and are less robust in preventing the development of obesity. Knowledge of this homeostatic system that controls body weight has increased exponentially over the last decade and has revealed new possibilities for the treatment of obesity and its associated comorbidities. One therapeutic target is the development of agents based on the gastrointestinal hormones that control appetite. This review discusses the hormones oxyntomodulin, peptide YY, glucagon-like peptide 1, pancreatic polypeptide, and ghrelin and their emerging potential as anti-obesity treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dc08-s269 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!